Zai Lab (NASDAQ:ZLAB) Stock Crosses Above Fifty Day Moving Average - Time to Sell?

Zai Lab logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zai Lab shares rose above their 50-day moving average, trading at $25.48 versus the average of $24.62.
  • Third-quarter results beat analyst estimates: the loss was $0.41 per ADS versus an expected $0.59, while revenue reached $108.21 million against a $107.90 million estimate. Reports differed on year-over-year trends, with some noting declining revenue and a wider loss.
  • Analysts’ consensus rating is Moderate Buy, with a $37.25 average price target; investors are watching pipeline milestones, including potential U.S. drug filings and progress expected toward 2027.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) crossed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $24.62 and traded as high as $25.99. Zai Lab shares last traded at $25.48, with a volume of 1,894,936 shares.

Zai Lab News Roundup

Here are the key news stories impacting Zai Lab this week:

  • Positive Sentiment: Zai Lab reported a third-quarter loss of $0.41 per ADS, narrower than analysts’ expected loss of about $0.59. Revenue of $108.21 million also slightly exceeded the $107.90 million estimate, providing a near-term earnings surprise. Earnings Flash
  • Positive Sentiment: Investors are also looking toward the pipeline: coverage highlighted the possibility of Zai Lab’s first U.S. drug filing and described 2027 as a pivotal year. Progress toward internally developed medicines could provide future growth catalysts, though outcomes remain uncertain. Zai Lab Q3 2026: Loss Narrows 27%, Pipeline Eyes First US Drug Filing UBS on Q3 performance and 2027
  • Neutral Sentiment: UBS said third-quarter performance met expectations, framing the main investment focus as execution on the milestones ahead rather than a major change in near-term results. UBS analysis
  • Negative Sentiment: Some earnings coverage said revenue declined and the reported quarterly loss widened, tempering the favorable comparison with analyst estimates. Sustained revenue growth and progress through the pipeline remain important to the outlook. Zai Lab Q3 Loss Widens, Revenue Declines

Wall Street Analyst Weigh In

A number of research firms recently commented on ZLAB. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Zai Lab in a report on Tuesday, October 27th. Cantor Fitzgerald reissued an "overweight" rating on shares of Zai Lab in a research report on Tuesday, October 6th. Citigroup upped their target price on Zai Lab from $44.00 to $45.00 and gave the company a "buy" rating in a report on Friday, August 7th. Finally, Wall Street Zen raised shares of Zai Lab from a "sell" rating to a "hold" rating in a report on Saturday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Zai Lab presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.25.

View Our Latest Analysis on ZLAB

Zai Lab Price Performance

The company's 50-day moving average price is $24.62 and its 200-day moving average price is $21.06. The company has a market cap of $2.90 billion, a P/E ratio of -14.23 and a beta of 0.77.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.18. Zai Lab had a negative return on equity of 27.43% and a negative net margin of 41.86%. The firm had revenue of $108.21 million during the quarter, compared to analyst estimates of $107.90 million. On average, equities research analysts predict that Zai Lab Limited Unsponsored ADR will post -2.37 EPS for the current year.

Insider Buying and Selling

In other Zai Lab news, Director William Lis sold 8,506 shares of the company's stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $25.00, for a total value of $212,650.00. Following the completion of the sale, the director directly owned 41,931 shares of the company's stock, valued at approximately $1,048,275. This represents a 16.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 9,385 shares of company stock valued at $235,145. 4.88% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zai Lab

Hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in Zai Lab during the 3rd quarter worth approximately $62,000. Nykredit A S bought a new stake in Zai Lab in the second quarter valued at $79,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Zai Lab during the third quarter valued at $211,000. WealthPlan Investment Management LLC bought a new stake in shares of Zai Lab in the third quarter valued at about $969,000. Finally, Headlands Technologies LLC grew its holdings in Zai Lab by 142.0% during the second quarter. Headlands Technologies LLC now owns 68,010 shares of the company's stock valued at $1,292,000 after purchasing an additional 39,901 shares during the period. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Zai Lab Company Profile

(Get Free Report)

Zai Lab Ltd. NASDAQ: ZLAB is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Zai Lab Right Now?

Before you consider Zai Lab, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.

While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines